Katarina Wikstrom has worked for over 20 years in the field of translational molecular oncology and holds the position of VP global product development at Almac Diagnostic Services.
RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.
Kate Broderick takes us on her intriguing journey - from being drawn to how science was applied within a medical setting, to the enormous challenge of working around the clock when the pandemic began.
Innova Biosciences says its Lightening-Link tech helps customers not to waste expensive reagents in antibody conjugation as it inks a supply deal with US Biological.
Thermo Fisher will up its list prices by an average of 3.3% across much of its early-stage bioproduction product range, reflecting changing market conditions.
Roche has added technology to tailor enzymes for specific applications in next-generation DNA and RNA sequencing through the acquisition of Kapa Biosystems.
Agilent Technologies has officially separated its biopharma service offerings from its electric measurement group to create two separate companies, the life science portion of which is expected to bring in about $3.9B in FY2013.
Thermo Fisher Scientific has set up a unit for molecular biology techs at its site in Lithuania, citing pharmaceutical R&D labs in Eastern Europe as a target.
Almac says its first leap into Next Generation Sequencing (NGS) data analysis services is a much needed-change from the industry’s current “one-size-fits-all” offering.
Boehringer Ingelheim Austria has been selected to win a Technology
Leadership award by Frost & Sullivan for its activities in the
contract manufacture of biotherapeutic proteins, and particularly
plasmid DNA.